Research programme: human monoclonal antibodies - MorphoSys/Pfizer
Latest Information Update: 01 Aug 2024
At a glance
- Originator MorphoSys; Pfizer
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in Germany (Parenteral)
- 31 Jan 2011 MorphoSys reaches a milestone in connection with an IND filing and initiation of a phase I trial of an antibody therapeutic in the area of oncology
- 20 Dec 2006 MorphoSys and Pfizer have expanded their collaboration on the development of therapeutic antibodies until 2011